Quantum Biopharma (QNTM) EPS (Weighted Average and Diluted) (2019 - 2026)
Quantum Biopharma's (QNTM) quarterly EPS (Weighted Average and Diluted) came in at $3.06 in Q1 2026, down 13.31% year-on-year from $3.53 in Q1 2025, and up 497.19% quarter-over-quarter from -$0.77 in Q4 2025.
Quantum Biopharma (QNTM) EPS (Weighted Average and Diluted) (2019 - 2026) Analysis & Trends
Quantum Biopharma has disclosed EPS (Weighted Average and Diluted) across 7 years of filings, most recently posting $3.06 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at $3.06, down 13.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.07 (down 2.98% YoY), and the FY2025 annual result was -$4.71, changed N/A from the prior year.
- EPS (Weighted Average and Diluted) came in at $3.06 for Q1 2026 at Quantum Biopharma, up from -$0.77 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $4.37 in Q3 2024 to a low of -$14.08 in Q2 2023.
- The 5-year median for EPS (Weighted Average and Diluted) is $0.66 (2024), against an average of $0.29.
- Across the five-year window, EPS (Weighted Average and Diluted) sank 2199.72% in 2023 and jumped 1342111013.76% in 2024, its largest moves.
- Quantum Biopharma's EPS (Weighted Average and Diluted) stood at -$0.0 in 2022, then tumbled by 5072836512.96% to -$0.56 in 2023, then surged by 875.18% to $4.37 in 2024, then sank by 117.63% to -$0.77 in 2025, then soared by 497.19% to $3.06 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $3.06 (Q1 2026), -$0.77 (Q4 2025), and $1.25 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 6.75 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.06 |
| Dec 31, 2025 | -0.77 |
| Sep 30, 2025 | 1.25 |
| Jun 30, 2025 | 3.23 |
| Mar 31, 2025 | 3.53 |
| Sep 30, 2024 | 4.37 |
| Jun 30, 2024 | 0.08 |
| Mar 31, 2024 | 3.43 |
| Sep 30, 2023 | -0.56 |
| Jun 30, 2023 | -14.08 |
| Mar 31, 2023 | 0.00 |
| Mar 31, 2022 | 0.00 |
| Jun 30, 2021 | 0.00 |
| Mar 31, 2021 | 0.00 |
| Dec 31, 2019 | -2.17 |